Fatigue Prognostic for Survival in Certain Patients With Myelodysplastic Syndromes

the ONA take:

Self-reported fatigue severity provides prognostic information for survival independent from gold-standard risk classifications in patients with newly diagnosed higher-risk myelodysplastic syndromes, a new study published online ahead of print in the journal The Lancet Oncology has shown.

Because the clinical presentation of myelodysplastic syndromes can be highly variable, researchers sought to evaluate whether self-reported fatigue severity is prognostic for overall survival in higher-risk patients.

For the study, researchers enrolled 280 patients with myelodysplastic syndromes who were enrolled within 6 months of diagnosis with an intermediate-2-risk or high-risk score.

Results showed that the median overall survival from diagnosis was 17 months. Researchers found that high-risk International Prognostic Scoring System (IPSS) score and a higher score for fatigue were independently associated with reduced overall survival. Self-reported fatigue remained a statistically significant prognostic factor for survival in further multivariate analyses.

“Our findings suggest that fatigue assessment should be included in routine diagnostic investigation for these patients and considered as a standard baseline stratification factor in future randomized controlled trials,” the authors conclude.

Fatigue Prognostic for Survival in Certain Patients With Myelodysplastic Syndromes
Self-reported fatigue severity provides prognostic information for newly diagnosed higher-risk myelodysplastic syndromes.
Self-reported fatigue severity provides prognostic information for survival independent from gold-standard risk classifications in patients with newly diagnosed higher-risk myelodysplastic syndromes, a new study published online ahead of print in the journal The Lancet Oncology has shown.
READ FULL ARTICLE From Thelancet
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs